1. Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18 F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study.
- Author
-
Rivers JP, Powell-Wiley TM, Dey AK, Rodante JA, Chung JH, Joshi AA, Natarajan B, Sajja AP, Chaturvedi A, Rana A, Harrington CL, Teague HL, Lockshin BN, Ahlman MA, Yao J, Playford MP, Gelfand JM, and Mehta NN
- Subjects
- Adult, Female, Humans, Intra-Abdominal Fat physiopathology, Longitudinal Studies, Male, Middle Aged, Predictive Value of Tests, Prognosis, Psoriasis physiopathology, Psoriasis therapy, Risk Factors, Subcutaneous Fat physiopathology, Time Factors, Vasculitis physiopathology, Vasculitis therapy, Whole Body Imaging, Adiposity, Fluorodeoxyglucose F18 administration & dosage, Intra-Abdominal Fat diagnostic imaging, Positron Emission Tomography Computed Tomography, Psoriasis diagnostic imaging, Radiopharmaceuticals administration & dosage, Subcutaneous Fat diagnostic imaging, Vasculitis diagnostic imaging
- Abstract
Objectives: The authors sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by
18 F-Fluorodeoxyglucose (18 F-FDG) positron-emission tomography (PET)/computed tomography (CT) in psoriasis (PSO). Furthermore, we evaluated whether treatment of PSO modulated VAT and VI., Background: PSO, a chronic inflammatory skin disease, is associated with VI by18 F-FDG PET/CT and increased cardiometabolic risk including adipose tissue dysregulation. Recently, VI was associated with future cardiovascular events; however, the relationship of visceral and subcutaneous adiposity with VI in PSO has yet to be evaluated., Methods: Consecutive PSO patients (N = 77) underwent18 F-FDG PET/CT scans to measure VI and abdominal adiposity. A subset of PSO patients with severe skin disease was scanned at 1 year following PSO treatment (N = 13)., Results: The cohort was middle aged (51.8 ± 12.6 years), predominantly male (n = 44, 57%), had low cardiovascular risk by Framingham 10-year risk (median 4 years [interquartile range (IQR): 2 to 7 years]), and mild-to-moderate skin disease (5.2 [IQR: 3.0 to 8.5]). PSO disease severity associated with VAT (β = 0.33; p = 0.004) beyond SAT (β = 0.30; p = 0.005). VAT (β = 0.55; p < 0.001), but not SAT (β = 0.15; p = 0.11), associated with VI beyond cardiovascular risk factors. We followed a subset of severe PSO patients treated aggressively for PSO and observed improvement in PSO severity and VAT, which was associated with an improvement in VI at 1 year beyond cardiovascular risk factors (β = 0.53; p = 0.049)., Conclusions: Volume-based CT measurement of VAT may capture metabolic risk associated with VI compared to subcutaneous adipose tissue in PSO. PSO treatment associated with a decrease in VAT as well as decrease in VI suggesting VAT as a relevant biomarker related to VI in PSO., (Published by Elsevier Inc.)- Published
- 2018
- Full Text
- View/download PDF